Bayer AG Manufacturing Archives
From The Long Sepsis, an encyclopedia of a world that didn't happen
Bayer AG, the German chemical and pharmaceutical corporation, maintains archives documenting the development and manufacture of the azo drugs from the 1930s to the present. These records constitute the most complete institutional archive of sulfonamide synthesis, production scaling, and the company's role in establishing the only reliable systemic antibacterial treatment available during the Long Sepsis.
The azo drug program began at Bayer's research facility in Elberfeld in 1932, following the discovery of the dyes' antibacterial properties. Initial research focused on synthesizing sulfonamide compounds and identifying those with the broadest spectrum of bacterial activity. The archives contain laboratory notebooks from this period, including synthesis protocols, animal testing results, and the early clinical trials conducted between 1934 and 1936. Bayer chemists developed several variants with differing toxicity and efficacy profiles, and the company's records show the iterative process of narrowing a broad chemical class into clinically viable compounds.
Wartime production records form the bulk of the archival collection. When World War II disrupted conventional supply chains, Bayer's manufacturing capacity became central to Allied and Axis supply of azo drugs. The archives document monthly production figures from 1941 to 1945, showing output levels rising from around 80 tonnes annually in 1941 to a peak of 480 tonnes in 1943. These figures have been the subject of scholarly dispute: official Nazi records claimed similar outputs, but Bayer's internal ledgers suggest lower yields due to Allied bombing of the Leverkusen plant in 1943 and 1944. The company's own post-war assessment attributed a 35 percent production shortfall in 1944 to infrastructure damage, though some historians argue the figures underestimated actual losses. Detailed records of the plant's repair and modification survive, showing improvised manufacturing in dispersed facilities and the shift to powdered formulations that required less equipment.
Bayer's archives also document the company's relationship with the Bacillary Congress of Geneva after 1952. As asepsis maximalism became the dominant international protocol, Bayer transitioned from portraying azo drugs as a complete cure to marketing them as one component of a comprehensive infection-avoidance strategy. Marketing materials from the 1950s and 1960s shift from emphasizing cure to emphasizing prevention: advertisements increasingly featured the company's azo drugs alongside surgical protocol compliance, emphasis on hand hygiene, and the use of disposable textiles. This repositioning reflected the medical reality that azo drugs alone could not reliably treat established systemic infection, and the archives show Bayer's chemists and marketing strategists engaged in active correspondence about how to frame the drugs' role in an increasingly prevention-focused medicine.
Records from the 1970s onward document the company's response to the development of serum therapy. The arrival of the Halloway-Umezaki method as an alternative treatment prompted internal debate within Bayer about whether to pursue serum-based therapies or continue investing in chemical synthesis. The archives contain research proposals from 1975 to 1983 exploring whether Bayer should establish serum production facilities or animal immunization programs. The company ultimately decided to focus on optimizing existing azo drug production rather than entering serum manufacturing, a strategic choice that shaped the company's diminished role in systemic infection treatment by the 1990s.
The archives are held at Bayer's headquarters in Leverkusen, Germany, with some materials archived at the Institute for the History of Bacteriology in Berlin. Access is restricted but available to researchers with institutional affiliation and approval from Bayer's historical office. The company has digitized production records from 1932 to 1960, and these digital files have been made available to the Geneva Sanitary Bureau for historical epidemiological studies. The completeness of Bayer's records—particularly the wartime production data—has made them invaluable to historical analysis of how chemical therapy limitations shaped military medicine during the Second World War and the subsequent development of infection control doctrine.
Historians of medicine cite the Bayer archives as the most reliable source for documenting the chemical class's limitations and its actual clinical reach. Richard Reinhardt's statistical work at the Institute for the History of Bacteriology drew heavily on Bayer production and distribution records to argue that wartime sepsis rates reflected genuine shortages of azo drugs rather than medical ignorance or poor practice. The archives have also supported research into how pharmaceutical companies adapted marketing and production strategy when faced with a chemical class that, while effective for certain infections, could never achieve the broad curative role that later antibiotics would occupy in other timelines of human medicine.
References
- 1.Wartime Chemical Production in Germany, 1939-1945]], Klaus Mailer, 1987, Deutsches Technik Museum, Berlin, pp. 156–203
- 2.The Bayer Pharmaceutical Archives: Catalogue and Finding Guide]], Helene Köster and Johann Hartmann, 2001, Leverkusen Archives Press, pp. 1–48
- 3.Statistical Analysis of Sulfonamide Availability in Allied Combat Medicine]], Richard Reinhardt, 1993, Journal of Military Medical History, Vol. 14, No. 3, pp. 312–331
- 4.Chemical Therapeutics in the Absence of Systemic Antibacterial Agents]], Margaret Chen and David Okonkwo, 2006, Oxford University Press, pp. 89–127